Report Summary

A regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses

Study Summary

Overall Study Design 
Preclinical and clinical data stress the importance of pharmacologically-controlling glial cell line-derived 
neurotrophic factor GDNF intracerebral administration to treat PD The main challenge is finding a 
combination of a genetic switch and a drug which when administered at a clinically-approved dose reaches the 
brain in sufficient amounts to induce a therapeutic effect We describe a highly-sensitive doxycycline-inducible 
adeno-associated virus AAV vector This vector allowed for the first time a longitudinal analysis of inducible 
transgene expression in the brain using bioluminescence imaging To evaluate the dose range of GDNF 
biological activity the inducible AAV vector 80 x 10e9 viral genomes was injected in the rat striatum at four 
delivery sites and increasing doxycycline doses administered orally 
More details on this study are available to registered users. To get access, you need to:
  1. Have an NGVB account: click here to create one
  2. Send an e-mail to the NGVB Manager to request access:

    NGVB Manager
    Please enable JavaScript in your browser to see the e-mail address.